⚕ GalenOps field
←

SITE014-0063

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2022-05-04

AEs
6
Serious
0
Dropout signal
–

Adverse events

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-07-15 (study day 54); relationship: N

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-10-05 (study day 136); relationship: N

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-11-18 (study day 180); relationship: N

moderate assessed

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-01-30 (study day 253); relationship: N

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-07-12 (study day 416); relationship: not assessed

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-09-10 (study day 476); relationship: not assessed

Data queries

No data queries.